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entoring may be the most important thing we
do on a daily basis. It produces some of our
greatest experiments and successes, our
mentees themselves. Ironically, although we
are fond of publishing data from diabetes research, we
never publish the results of our mentoring in contempo-
rary literature. We must turn to oral and written history to
even deﬁne the word “mentoring.” What exactly is it?
A modestly revised version of Greek mythology. The
word “mentor” evolved from Homer’s opus, The Odyssey.
Odysseus (or Ulysses, his other name) was a graduate of
Cornell University and became King of Ithaca. He was very
conﬂicted about ﬁghting the Trojan War. To avoid going to
battle, he pretended to be crazy by plowing his ﬁeld with
salt. However, the Greek military was suspicious and
tested Odysseus by putting his newly born son, Telema-
chus, in front of his plow. Odysseus stopped plowing to
save his son. Having thus demonstrated his sanity and
blown his cover, Odysseus joined the army and sailed up
the wine-dark Aegean Sea to Troy where he entered
graduate school in the Greek War College. His research
project was to ascertain the effect of wooden horses on
warfare. Before leaving Ithaca, Odysseus had asked an
elderly friend named Mentor to provide advice to Telema-
chus, as well as to his lovely wife Penelope.
After ﬁghting the Trojans for 10 years and defeating them,
Odysseus received his ﬁrst patent for inventing the Trojan
horse and in many other ways distinguished himself in
wisdom and leadership. He received his PHD in Creative
Combat and then started out on his victorious trip home,
sailing south and seeing the sights in the Aegean Sea.
However, he encountered storms, took several wrong turns,
and wound up traveling around the southern Mediterranean,
Tyrrhenian, and Ionian seas for 10 more years. This became
his ﬁrst postdoctoral experience. During his travels he es-
caped the lethargic land of the Lotus eaters in Tunisia;
conquered Cyclops, a Sicilian monster; confounded sirens off
the coast of Italy by having himself tied to the mast and
putting wax in his sailors’ ears; and escaped a six-headed
monster in the straits of Messina. Finally, he made his way
back home to Ithaca disguised as a beggar.
Faithful Penelope had been ﬁghting off unwelcome
suitors those 20 years and failed to recognize Odysseus at
ﬁrst when he returned. But his faithful old dog did, wagged
his tail, and promptly dropped dead of old age. Odysseus
then identiﬁed himself to his family and to Mentor. To-
gether they hatched a plot to get rid of the suitors.
Penelope fetched an old bow used by Odysseus and
challenged her suitors to demonstrate their prowess with
it. You can see the happy ending coming. None of the
suitors were strong enough to string the bow. Odysseus
did so easily and with it killed Penelope’s suitors. Like a
true mentor, the good counselor Mentor simply faded into
the background and took no credit.
Diabetologists as mentors. What does all this have to
do with mentoring within the American Diabetes Asso-
ciation (ADA)? As scientists, clinicians, educators, and
health care providers, we mentor all day long. We train
younger professionals who come into our labs, clinics,
and classrooms. They come to learn theory and proce-
dures. They seek our words of wisdom on all sorts of
things: how to properly form and test hypotheses, how
to run a gel; how to program an insulin pump, how to
juggle drugs to prod our patients’ sluggish -cells, how
to formulate optimal diets for our patients, and how to
educate the public about social and ﬁnancial impacts of
diabetes. Senior mentees next begin to mentor junior
mentees—students and patients—and thus the cycle of
mentoring is played forward. Then an amazing thing
happens. The very people we are mentoring begin to
mentor us. There is a name for this: reverse mentoring.
Students and fellows bring us new information from the
Internet. On rare and miraculous occasions of un-
guarded curiosity when their computers are down, they
even go to libraries and ﬁnd information for us from
real, rather than virtual, journals.
Many of us have the special privilege of mentoring
diabetic patients and their families. We serve as coaches
for these truly impressive athletes as they struggle with,
adapt to, and overcome major challenges that never seem
to relent. If we listen carefully, they also mentor us. They
often teach us ways they have discovered to better control
their personal glycemic swings. They help us to under-
stand that today’s improved methods of diabetes care are
not always available to all people in all cultures.
Perhaps the most intense mentoring we experience
comes in the form of study sections, manuscript reviews,
and accreditation committees. Admittedly, these experi-
ences may not be always thought of as mentoring—maybe
some other kind of experience. Perhaps they represent our
own Greek odyssey ﬁlled with perceived monsters and
dangers such as conﬂicts of interest, professional jealou-
sies, passive aggressiveness, or at best just plain obtuse-
ness. As an example, think again of Odysseus tied to the
mast, feeling helpless. Perhaps he has just submitted his
proposal for a junior faculty award. The study section
rowing his boat still has wax in the ears and does not
appear to be listening.
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mentoring experiences in professional life. My friends in
the business world are amazed by this. What group of
businessmen would agree to review their colleagues’ work
with a ﬁne-tooth comb, climb onto airplanes to ﬂy to
Washington DC, and then spend days away from their
families and their own work to provide valuable consulta-
tion? All this with no signiﬁcant ﬁnancial compensation.
Surely, we are a unique group of professionals mentoring
and teaching fellow professionals, which brings me to this
year’s Scientiﬁc Sessions.
Sixty-nine years of annual medicine: science meet-
ings. This annual migration of people interested in
diabetes began 69 years ago. The ﬁrst ADA Scientiﬁc
Sessions was held in Cleveland, Ohio, in 1941, with 250
physicians in attendance at the Hotel Hollenden (it is
curious but noteworthy that Cleveland is located just
southwest of a town called Mentor in northeastern
Ohio). The program listed a grand total of ﬁve presen-
tations. Of interest, it was 14 years later, in 1955, that
ADA awarded its ﬁrst two research fellowships to two
young scientists. One of them worked in the laboratory
of Dr. Albert Renold. Today, in his memory, the ADA
annually grants a prestigious award for mentoring, the
Albert Renold Medal. By the mid-1960s, diabetes had
tripled in incidence compared with 20 years previously—
sounds similar to today’s epidemiologic trends. The book
entitled The Journey and the Dream, a history of ADA,
tells us that in 1970 ADA reorganized into a voluntary
health agency with the primary goal of funding research.
That phrase is worth repeating: with the primary goal of
funding diabetes research. When I presented my ﬁrst ADA
talk in 1972 in San Francisco, California, the audience ﬁt
into two rooms in the Sheraton Palace Hotel. The program
consisted of 62 talks and 108 abstracts, and poster ses-
sions were nonexistent.
Things look very different these days. I don’t have all the
data for this year’s Scientiﬁc Sessions, but here is how they
looked last year, in 2008:
● Pages in the meeting program: 1,034
● Abstracts presented orally: 397
● Total abstracts submitted: 2,879
● Attendance: 20,562
● Attendees from the Americas: 59%
● Attendees from Europe: 35%
● Attendees from Asia and the Paciﬁc: 6%
The medical and scientiﬁc progress that attracts us to
this meeting has come at a price. We now meet in
gargantuan halls that no hotel in Cleveland could accom-
modate. We encounter more strangers than we greet
familiar colleagues. The Greek god Hermes comes to
mind. We all could use his winged feet, or at least track
shoes, to get from one session to another. Our sheer size
limits the number of cities that can handle us. Old timers
suffer from painful nostalgia of smaller meetings 40 years
ago. Our Scientiﬁc Sessions is increasingly confronted
with enormity and anonymity.
To keep a human dimension to this large meeting, steps
we have already taken include keeping some interest
groups in one meeting room for most of the Scientiﬁc
Sessions. Doing this conveys the sense of a smaller
meeting but still enables attendees to go to the larger
sessions and exhibit hall. We are exploring whether we
should expand this concept to other interest groups.
Certainly, we do not want to lose the opportunity to hear
what is going on in all areas related to diabetes. We know
that learning about developments in one area of science
often gives us ideas about what we might do in our own
area of expertise. However, we need to ﬁnd more effective
ways of providing easier access for younger scientists and
clinicians to their more established colleagues in a more
social, user-friendly environment. This will facilitate ex-
change of ideas and experiences as well as identify new
academic and employment opportunities for postdoctor-
ate scholars and faculty.
Working as one ADA. I mentioned earlier that ADA and
the ﬁeld of diabetes have grown enormously in the past
69 years. Yet the number of research awards we give has
barely grown at all. Recognition of excellence is an
important aspect of our professional lives, so we have
begun to reexamine how we do it. Recently, ADA has
convened a dedicated group that studied this issue, and
it has recommended an award process that will more
completely recognize the excellence in our various
disciplines. Stay tuned; you will hear more about this
later in the year.
In other important news, we have just begun a series of
meetings with The Endocrine Society. Our joint goal is to
identify how we can work together to foster quality
medical care and to inﬂuence public policy issues. This
seems only sensible given our limited resources and the
huge amount of work in diabetes and obesity we can
tackle together.
This meeting is focused on reporting progress in medi-
cine and science, which raises the question, what have we
accomplished during all the years since 1941? Thumbing
through abstract books published over the past 40 years
relates clearly that the scientiﬁc and clinical material
presented at our meetings has greatly escalated in quality
and quantity. Yet, the cure of diabetes continues to elude
us. The current global epidemic of diabetes tells us we are
not winning this war. The startling appearance of type 2
diabetes in our youth alarms us. The parallel epidemic in
obesity greatly compounds the problem of diabetes. These
incontrovertible facts reinforce the obvious that we must
work harder, think more creatively, and achieve our
scientiﬁc goals more quickly.
This is easily said but hard to do. Just dreaming about
accelerating diabetes research will not do the job. A
successful response to these demands will come only at a
price. We must seriously increase the ﬁscal support of
research provided by ADA as well as all potential funding
sources to more vigorously fund research that will allow
us to overcome this disease. In terms of ADA funding,
there is good and bad news. The good news is we have had
a steep rise in research funding since the mid-1990s. The
bad news is that research support reached a plateau over
the past 4 years. Other good news is that the number of
grants funded by ADA has not decreased over the past
year, when some organizations severely cut back their
funding of diabetes research altogether. The worst news is
that fundraising by ADA and its investment portfolio have
been hit especially hard by the economy in 2009. This has
led to a layoff of ADA staff nationally as well as a decrease
in funds available to support our research program. Con-
sequently, we had to do something to manage this
problem.
The choices for ADA research were to stop funding new
grants completely beginning July 2009 or to ﬁnd a way to
distribute less money evenly among all grantees. The
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stop funding new research. There are too many new ideas,
exciting opportunities, and excellent diabetes investiga-
tors to permit this. Consequently, our strategy will be to
administratively decrease budgets of our new and current
grants, in roughly the same manner we have seen at the
National Institutes of Health over the past 2 years. This is
certainly discouraging but not devastating news. Although
painful, this strategy will allow us to ensure that the ADA
research program is still open for business and still
funding new research. We will use the message that ADA
is still funding new research as a strong incentive for
greater fundraising so that we can become ﬁnancially
whole again.
Moreover, the Executive Committee of ADA has re-
solved that as soon as the economic situation at ADA
recovers, the ﬁrst program to be ﬁnancially restored will
be its research program. ADA recognizes that we have
come too far to falter. We have had too many glimpses of
cures on the horizon to bog down in despair. We know that
failure is not an option. We have trained too many young
basic and clinical scientists to abandon their futures,
which once again brings me back to mentoring.
We as an organization and as individuals must mentor
society and government about the need to fund diabetes
research. We need to let people know what it will take to
translate our scientiﬁc and clinical knowledge into preven-
tion and more successful clinical management of diabetes.
We need to educate one another about the massive strides
ADA has made in issues of advocacy for patients with
diabetes and their families. We need to appreciate and
support the ADA’s relentless efforts to raise more money
and make us a more effective organization. We must
remember that we are all colleagues on this journey.
Our biggest fundraising event throughout the nation
takes place in October. Its name is Step Out. We need to
thank our fundraisers for what they have done in the past
and now ask them to work even harder. Those of us from
the U.S. need to participate more fully in these fundraising
events by walking further, golﬁng better, biking longer,
running faster, contacting more potential donors, and
digging deeper into our own pockets to fund ADA
research.
The various interest groups in ADA are major resources
for our mission. They have been immensely successful in
many ways. Yet, we are smart enough to realize that we
will get further faster by working together as one large
force to reach our many objectives. Borrowing a page
from President Obama’s playbook, let me say that the best
plan is for there to be no separate departments for Science
and Medicine ADA, no Fundraising ADA, no Administra-
tion ADA, no Advocacy ADA, and no Education and Health
Care ADA. The best plan is for there to be only one ADA
and that ADA is all of us working together to do what we
must do to gain control over this disease and all its
complications.
Personal lessons learned from mentees. I want to
ﬁnish this address by focusing on the futures of the
younger scientists and clinicians we have mentored. I have
been privileged to mentor many special people at the
Universities of Washington, Colorado, and Minnesota. It is
their hard work and dedication that led to our publica-
tions. During all these years, I have learned something
special from each of them: examples of reverse mentoring.
We know that training and supporting young people such
as these have become increasingly more complicated for a
variety of reasons. This makes our jobs as mentors even
more essential. We know our mentoring will provide more
promise for the future than anything else we can do. We
know that our greatest personal legacies will be the
provision of tomorrow’s leaders.
This causes us to consider: what are the characteristics
of a successful mentor? Here are some of the lessons my
mentees have taught me.
To mentor is:
● to be a selﬂess senior colleague
● to listen and understand personal and professional
dilemmas
● to teach mentees problem-solving skills but, at the same
time, refrain as much as possible from solving problems
for them
● to follow up on mentoring sessions to hear outcomes of
decisions made and to consider alternative courses of
action when needed
● to guide ﬁrmly initially but increasingly let go at the
earliest opportunity
● to maintain strict conﬁdentiality
● to encourage and celebrate and to give spontaneous
hugs and high ﬁves whenever and wherever warranted
● to understand that when serious personal interventions
are needed, they should be provided and although this
can be difﬁcult, to understand it is the essence of being
loyal
● to stand back and take quiet personal pride in mentees’
successes and to avoid taking any credit for them
● to suffer in silence around junior colleagues when one’s
own personal problems with grant or manuscript re-
views plague us and to focus on encouraging, not
discouraging, the dedicated men and women who come
to us to learn and to carry our batons and their torches
into the future
● above all, to always remember that, to paraphrase
astronaut Christa McCullough’s inspiring words, when
we mentor, we touch the future. It can be an awesome
experience.
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